Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
INVO Fertility, Inc. (IVF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: IVF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -76.66% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.90 - 17.04 | Updated Date 05/27/2025 |
52 Weeks Range 0.90 - 17.04 | Updated Date 05/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
INVO Fertility, Inc.
Company Overview
History and Background
INVO Fertility, Inc. is a fertility company focused on commercializing the INVOcell solution, an alternative to traditional IVF. Founded to address affordability and accessibility issues in fertility treatment, it has evolved through strategic acquisitions and partnerships to expand its market presence.
Core Business Areas
- INVOcell Solution: Commercialization and distribution of the INVOcell device, a patented intravaginal culture system for simpler and more natural fertility treatment.
- Clinic Network: Operation and management of INVO Centers, providing fertility services directly to patients. The INVO Centers strategy aims to drive adoption of the INVOcell solution.
Leadership and Structure
The leadership team consists of key executives overseeing operations, finance, and marketing. Organizational structure includes departments focused on sales, clinical operations, and research and development.
Top Products and Market Share
Key Offerings
- INVOcell: The INVOcell device is the core product. It enables intravaginal culture, reducing the need for extensive lab infrastructure. Limited market share data available. Competitors include traditional IVF procedures offered by larger fertility clinics and pharmaceutical companies selling fertility drugs.
Market Dynamics
Industry Overview
The fertility market is growing due to increasing infertility rates, rising disposable incomes, and advancements in reproductive technologies. Key trends include a focus on personalized medicine and less invasive treatments.
Positioning
INVO Fertility positions itself as a provider of accessible and affordable fertility treatment through the INVOcell solution. Its competitive advantage lies in its simpler and potentially more natural approach compared to traditional IVF.
Total Addressable Market (TAM)
The global fertility market is estimated at tens of billions of dollars. INVO Fertility, with its focus on affordability and accessibility, aims to capture a portion of this TAM by reaching underserved patient segments.
Upturn SWOT Analysis
Strengths
- Proprietary INVOcell technology
- Focus on affordability and accessibility
- Potential for expanded market reach in underserved areas
Weaknesses
- Limited market share compared to established IVF providers
- Reliance on INVOcell adoption
- Financial constraints and need for capital
Opportunities
- Expansion into new geographic markets
- Partnerships with fertility clinics and healthcare providers
- Increased awareness and acceptance of intravaginal culture
Threats
- Competition from established IVF providers
- Regulatory hurdles and approval processes
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- CRTX
- FERT
- TSRI
Competitive Landscape
INVO Fertility faces competition from established IVF clinics with greater resources and brand recognition. Its advantage is its focus on affordability and a simpler procedure. Its disadvantage is the lower adoption rate and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the adoption of INVOcell and the expansion of the INVO Center network.
Future Projections: Future growth is expected to come from continued market penetration, strategic partnerships, and potentially new product developments. Analyst estimates will be variable.
Recent Initiatives: Recent initiatives include expanding the INVO Center network, focusing on partnerships and increasing marketing efforts to raise awareness of INVOcell.
Summary
INVO Fertility is a fertility company with a proprietary technology aimed at affordability. It faces competition from established IVF providers. Growth depends on INVOcell adoption and expansion of its clinic network. Maintaining financial stability and gaining market share are key challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About INVO Fertility, Inc.
Exchange NASDAQ | Headquaters Sarasota, FL, United States | ||
IPO Launch date 2012-05-21 | CEO & Director Mr. Steven M. Shum | ||
Sector Healthcare | Industry Medical Devices | Full time employees 33 | Website https://www.invobioscience.com |
Full time employees 33 | Website https://www.invobioscience.com | ||
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services; INVOcell Device; and Therapeutics segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. It also operates fertility clinics, including INVO Centers. In addition, the company develops NY-303, a GPC3 x NKp46 bifunctional antibody that is in Phase i/ii a monotherapy trial for the treatment of hepatocellular carcinoma; and NY-500, an AI-optimized bifunctional antibody. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.